Premium
Quinidine‐induced thrombocytopenic purpura: clinical presentation in relation to drug‐dependent and drug‐independent platelet antibodies
Author(s) -
Nieminen Urpo,
Kekomäki Riitta
Publication year - 1992
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1992.tb06403.x
Subject(s) - medicine , immunofluorescence , antibody , thrombocytopenic purpura , discontinuation , platelet , drug , quinidine , immunology , platelet glycoprotein gpib ix complex , monoclonal antibody , platelet membrane glycoprotein , pharmacology
Summary. We have studied the clinical course of quinidineinduced thrombocytopenia in relation to the presence of drug‐dependent (dd‐ab:s) and drug‐independent antibodies in 14 patients. Thrombocytopenia was reversible in 9 d after discontinuation of quinidine treatment in 10 patients. In four it lasted more than 1 month. Drug‐dependent antibodies of IgG class were detectable in seven patients: in six by an immunofluorescence test applying flow cytometry and in one patient by a monoclonal antibody‐immobilized platelet protein assay (MAIPA) only. The dd‐ab:s of this patient had glycoprotein (GP) IIIb/IIIa specificity. Five of the six patients with dd‐ab:s by immunofluorescence test had GPIb/IX‐specific dd‐ab:s by MAIPA. They recovered within 5 d after discontinuation of the drug. All four patients with prolonged thrombocytopenia had elevated platelet‐associated IgG (PAIgG) in the acute phase as studied by a direct platelet immunofluorescence test. The remaining five patients displayed a relatively rapid clinical recovery but less uniform pattern of immunological findings. The results suggest that patients with GPIb/IX‐specific dd‐ab:s recover promptly despite an acute and profound thrombocytopenia. Another sub‐group with prolonged thrombocytopenia had persistently elevated PAIgG during the convalescent phase.